Jazz Pharmaceuticals (JAZZ) Other Non Operating Income (2010 - 2026)

Jazz Pharmaceuticals' Other Non Operating Income history runs 16 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Other Non Operating Income rose 1350.0% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $145000.0, a 102.17% increase from a year earlier, with the FY2025 full-year figure at -$2.6 million, up 68.61% from the prior year.
• Other Non Operating Income improved to $2.5 million in Q1 2026 per JAZZ's latest filing, from -$658000.0 in the prior quarter.
• Across five years, Other Non Operating Income topped out at $9.4 million in Q4 2023 and bottomed at -$10.5 million in Q1 2022.
• The 5-year median for Other Non Operating Income is -$1.3 million (2022), against an average of -$1.1 million.
• Across the five-year window, Other Non Operating Income slumped 1217.71% in 2022 and soared 1350.0% in 2026, its largest moves.
• Year by year, Other Non Operating Income stood at -$2.5 million in 2022, then surged by 476.83% to $9.4 million in 2023, then plunged by 167.3% to -$6.3 million in 2024, then jumped by 89.55% to -$658000.0 in 2025, then soared by 479.94% to $2.5 million in 2026.
• Per Business Quant, the three latest JAZZ Other Non Operating Income figures stand at $2.5 million (Q1 2026), -$658000.0 (Q4 2025), and $102000.0 (Q3 2025).